Subvisible Particles in IVIg Formulations Activate Complement in Human Serum

Overview

Journal J Pharm Sci

Publisher Elsevier

Specialties Pharmacology
Pharmacy

Date 2019 Nov 2

PMID 31672401

Citations 5

Authors

Carly F Chisholm

William Behnke

Yekaterina Pokhilchuk

Ashley A Frazer-Abel

Theodore W Randolph

Affiliations

Soon will be listed here.

Abstract

When administered intravenously, various particles and nanomedicines activate complement, potentially leading to infusion reactions and other adverse drug reactions. Particles form within formulations of therapeutic proteins due to stresses incurred during shipping, handling, and administration to patients. In this study, IVIg solutions were stored in multiple types of vials and prefilled syringes and exposed to agitation and freeze-thaw stresses to generate particles. The stressed samples were added to human serum to determine whether these particles activated complement. Subvisible IVIg particles ranging in size between 2 and 10 microns activated complement in a fashion that was linearly dependent on the number of particles dosed, whereas little correlation was found between doses of larger particles (>10 microns) and complement activation. Activation of complement by subvisible particles of IVIg followed the alternative pathway, as shown by the release of complement cascade factor Bb and the production of the anaphylatoxins C3a and C5a without generation of C4a. The number and the morphology of subvisible particles formed depended on the applied stress, formulation, and on the container material. But the capacity of the 2- to 10-micron-sized particles to activate complement in human serum appeared to depend only on particle concentration.

Citing Articles

pH-Dependent Conformational Plasticity of Monoclonal Antibodies at the SiO/Water Interface: Insights from Neutron Reflectivity and Molecular Dynamics.

Li Z, Saurabh S, Hollowell P, Kalonia C, Waigh T, Li P ACS Appl Mater Interfaces. 2024; 16(51):70231-70241.

PMID: 39663899 PMC: 11672230. DOI: 10.1021/acsami.4c14407.

Submicron immunoglobulin particles exhibit FcγRII-dependent toxicity linked to autophagy in TNFα-stimulated endothelial cells.

Hollis W, Farooq S, Khoshi M, Patel M, Karnaukhova E, Eller N Cell Mol Life Sci. 2024; 81(1):376.

PMID: 39212707 PMC: 11364738. DOI: 10.1007/s00018-024-05342-9.

Biochemical Characterization of a New 10% IVIG Preparation [IgG Next Generation (BT595)/Yimmugo] Obtained from a Manufacturing Process Preserving IgA/IgM Potential of Human Plasma.

Duellberg C, Hannappel A, Kistner S, Maneg O Drugs R D. 2023; 23(3):245-255.

PMID: 37466834 PMC: 10439088. DOI: 10.1007/s40268-023-00430-w.

Immunogenicity Risk Assessment of Spontaneously Occurring Therapeutic Monoclonal Antibody Aggregates.

Swanson M, Rios S, Mittal S, Soder G, Jawa V Front Immunol. 2022; 13:915412.

PMID: 35967308 PMC: 9364768. DOI: 10.3389/fimmu.2022.915412.

Modulating Nanoparticle Size to Understand Factors Affecting Hemostatic Efficacy and Maximize Survival in a Lethal Inferior Vena Cava Injury Model.

Hong C, Alser O, Gebran A, He Y, Joo W, Kokoroskos N ACS Nano. 2022; 16(2):2494-2510.

PMID: 35090344 PMC: 9989960. DOI: 10.1021/acsnano.1c09108.

References

Kiese S, Papppenberger A, Friess W, Mahler H . Shaken, not stirred: mechanical stress testing of an IgG1 antibody. J Pharm Sci. 2008; 97(10):4347-66. DOI: 10.1002/jps.21328. View

Ordas I, Feagan B, Sandborn W . Therapeutic drug monitoring of tumor necrosis factor antagonists in inflammatory bowel disease. Clin Gastroenterol Hepatol. 2012; 10(10):1079-87. DOI: 10.1016/j.cgh.2012.06.032. View

Nejadnik M, Randolph T, Volkin D, Schoneich C, Carpenter J, Crommelin D . Postproduction Handling and Administration of Protein Pharmaceuticals and Potential Instability Issues. J Pharm Sci. 2018; 107(8):2013-2019. DOI: 10.1016/j.xphs.2018.04.005. View

Szebeni J, Alving C, Savay S, Barenholz Y, Priev A, Danino D . Formation of complement-activating particles in aqueous solutions of Taxol: possible role in hypersensitivity reactions. Int Immunopharmacol. 2001; 1(4):721-35. DOI: 10.1016/s1567-5769(01)00006-6. View

Kotarek J, Stuart C, De Paoli S, Simak J, Lin T, Gao Y . Subvisible Particle Content, Formulation, and Dose of an Erythropoietin Peptide Mimetic Product Are Associated With Severe Adverse Postmarketing Events. J Pharm Sci. 2016; 105(3):1023-7. DOI: 10.1016/S0022-3549(15)00180-X. View

Rosenberg A . Effects of protein aggregates: an immunologic perspective. AAPS J. 2006; 8(3):E501-7. PMC: 2761057. DOI: 10.1208/aapsj080359. View

Gerhardt A, Mcgraw N, Schwartz D, Bee J, Carpenter J, Randolph T . Protein aggregation and particle formation in prefilled glass syringes. J Pharm Sci. 2014; 103(6):1601-12. DOI: 10.1002/jps.23973. View

Malucchi S, Sala A, Gilli F, Bottero R, Di Sapio A, Capobianco M . Neutralizing antibodies reduce the efficacy of betaIFN during treatment of multiple sclerosis. Neurology. 2004; 62(11):2031-7. DOI: 10.1212/01.wnl.0000129265.73259.9e. View

Weiszhar Z, Czucz J, Revesz C, Rosivall L, Szebeni J, Rozsnyay Z . Complement activation by polyethoxylated pharmaceutical surfactants: Cremophor-EL, Tween-80 and Tween-20. Eur J Pharm Sci. 2011; 45(4):492-8. DOI: 10.1016/j.ejps.2011.09.016. View

10.

Moghimi S, Simberg D, Skotland T, Yaghmur A, Hunter A . The Interplay Between Blood Proteins, Complement, and Macrophages on Nanomedicine Performance and Responses. J Pharmacol Exp Ther. 2019; 370(3):581-592. PMC: 11047092. DOI: 10.1124/jpet.119.258012. View

11.

Choquette D, Faraawi R, Chow A, Rodrigues J, Bensen W, Nantel F . Incidence and Management of Infusion Reactions to Infliximab in a Prospective Real-world Community Registry. J Rheumatol. 2015; 42(7):1105-11. DOI: 10.3899/jrheum.140538. View

12.

Pardeshi N, Zhou C, Randolph T, Carpenter J . Protein Nanoparticles Promote Microparticle Formation in Intravenous Immunoglobulin Solutions During Freeze-Thawing and Agitation Stresses. J Pharm Sci. 2018; 107(7):1852-1857. PMC: 6245654. DOI: 10.1016/j.xphs.2018.03.016. View

13.

Moghimi S, Hunter A . Complement monitoring of nanomedicines and implants. Adv Drug Deliv Rev. 2011; 63(12):963-4. DOI: 10.1016/j.addr.2011.06.008. View

14.

Vlieland N, Gardarsdottir H, Bouvy M, Egberts T, van den Bemt B . The majority of patients do not store their biologic disease-modifying antirheumatic drugs within the recommended temperature range. Rheumatology (Oxford). 2015; 55(4):704-9. DOI: 10.1093/rheumatology/kev394. View

15.

Szebeni J, Baranyi L, Savay S, Milosevits J, Bunger R, Laverman P . Role of complement activation in hypersensitivity reactions to doxil and hynic PEG liposomes: experimental and clinical studies. J Liposome Res. 2003; 12(1-2):165-72. DOI: 10.1081/lpr-120004790. View

16.

Atwal D, Safar A, Govindarajan R, Makhoul I . Severe first infusion reaction related to cetuximab in cancer patients in Arkansas. J Oncol Pharm Pract. 2018; 25(5):1130-1134. DOI: 10.1177/1078155218780514. View

17.

Chanan-Khan A, Szebeni J, Savay S, Liebes L, Rafique N, Alving C . Complement activation following first exposure to pegylated liposomal doxorubicin (Doxil): possible role in hypersensitivity reactions. Ann Oncol. 2003; 14(9):1430-7. DOI: 10.1093/annonc/mdg374. View

18.

Agbeko R, Fidler K, Allen M, Wilson P, Klein N, Peters M . Genetic variability in complement activation modulates the systemic inflammatory response syndrome in children. Pediatr Crit Care Med. 2010; 11(5):561-7. DOI: 10.1097/PCC.0b013e3181d900ba. View

19.

Diebolder C, Beurskens F, de Jong R, Koning R, Strumane K, Lindorfer M . Complement is activated by IgG hexamers assembled at the cell surface. Science. 2014; 343(6176):1260-3. PMC: 4250092. DOI: 10.1126/science.1248943. View

20.

Klos A, Tenner A, Johswich K, Ager R, Reis E, Kohl J . The role of the anaphylatoxins in health and disease. Mol Immunol. 2009; 46(14):2753-66. PMC: 2725201. DOI: 10.1016/j.molimm.2009.04.027. View